Ajinomoto Co., Ltd.

Toshihiko Yoshimura

Masahiro Murata

Eiji Nakanishi

Hiroyuki Izawa

Nobuyasu Suzuki

Tatsuya Okuzumi

Kazuyuki Sagi

Shingo Makino

Takashi Tsuji

Yuko Satake

Akira Chiba

Naoyuki Fukuchi

Hideyuki Tanaka

Yasuhiro Tanaka

Manabu Suzuki

Yuji Tanaka

Katsumi Maezono

Yoichiro Shima

Nozomu Ishida

Yayoi Kawato

Chieko Ejima

Mitsuhiko Kojima

Miho Ono

Akiko Oonuki

Tamotsu Suzuki

Tadakiyo Nakagawa

Shinichi Fujita

Youji Yamada

Masanao Yoshida

Kaoru Takenaka

Hideki Matsumoto

Toshihiko Ando

Manabu Kitazawa

Masayuki Sugiki

Toshihiro Hatanaka

Munetaka Tokumasu

Mitsuo Takahashi

Yuka Ikenoue

Osamu Ikehara

Haruko Hirashima

Ryosuke Fudo

Yasuko Nogi

Yoko Obayashi

Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to &#x3b1;4 integrin. They are used as therapeutic agents for various diseases concerning &#x3b1;4 integrin. 

Phenylalanine derivatives

Amide derivatives represented by the formula (I): wherein:

Amide derivative

The present invention provides PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.

PPAR activity regulators

Phenylalanine derivatives of the following formula, analogues thereof and pharmaceutically acceptable salts thereof have an antagonistic activity to &#x3b1;4 integrin. They are used as therapeutic agents or preventive agents for various diseases concerning &#x3b1;4 integrin in which &#x3b1;4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sj&#xf6;gren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection. wherein R1 is a methyl group and R2 is a methoxy group.

The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds are represented by the formulas (A), (B), (C), (E) and (H): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

Aniline derivatives

Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the &#x3b1; 4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which &#x3b1; 4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sj&#xf6;gren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

The present invention provides an acylamide compound of the following formula (1), prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, therapeutic agent of metabolic syndromes, therapeutic agent of hypoadiponectinemia, therapeutic agent of hyperlipemia, preventive/therapeutic agent of diabetes, improving agent of impaired glucose tolerance, improving agent of insulin resistance, enhancing agent of insulin sensitivity, therapeutic agent of hypertension, preventive/therapeutic agent of vascular disorders, an anti-inflammatory agent, therapeutic agent of hepatic inflammation, therapeutic agent of fatty liver, therapeutic agent of hepatic fibrosis, therapeutic agent of liver cirrhosis, preventive/therapeutic agent of non-alcoholic/nonviral steatohepatitis (NASH) or non-alcoholic/nonviral fatty liver disease (NAFLD), or therapeutic agent of obesity, each of which has the above compounds as an active ingredient. 

Acylamide compounds having secretagogue or inducer activity of adiponectin

The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing/treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity. The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.

The present invention relates to the following phenylalanine derivatives or analogues thereof having an antagonistic activity to &#x3b1;4 integrin and therapeutic agents for various diseases concerning &#x3b1;4 integrin. 

Specified phenylpropionic acid derivatives and analogues thereof have an antagonistic activity to &#x3b1; 4 integrin. They are used as therapeutic agents or preventive agents for various diseases concerning &#x3b1; 4 integrin, such as inflammatory diseases in which &#x3b1; 4 integrin-depending adhesion process participates in the pathology, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sj&#xf6;gren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

Phenylpropionic acid derivatives

Growing community of inventors

Kawasaki, Japan

Toshihiko Yoshimura